BioRestorative Therapies, Inc. · NASDAQ:BRTX

BioRestorative Therapies — ASGCT 2019

14 slides from BioRestorative Therapies's conference presentation, April 2019

  1. Slide 1: ASGCT 2019 – General Presentation

    ASGCT 2019– General Presentation

  2. Slide 2: Disclaimer

    Disclaimer STATEMENTS IN THIS INVESTMENT SUMMARY (“SUMMARY”), INCLUDING THE INFORMATION SET FORTH AS TO THE FUTURE FINANCIAL OR OPERATING PERFORMANCE OF BIORESTORATIVE THERAPIES, INC. (THE “COMPANY” OR “BRT”), THAT ARE NOT CURRENT OR HISTORICAL FACTUAL STATEMENTS MAY CONSTITUTE “FORWARD LOOKING” INF

  3. Slide 3: Mass of BAT is Inversely Correlated with Obesity and Unhealthy Metabolism

    Mass of BAT is Inversely Correlated with Obesity and Unhealthy Metabolism • Obesity is a worldwide epidemic • In the U.S., 37% of adults and 16.9% of children and adolescents are obese • Obesity is a risk factor for insulin- resistance, metabolic syndrome, and cardiovascular disease • In 2012, the t

  4. Slide 4: Brown Adipose Tissue – Novel Therapeutic to Treat Obesity and Related Metabolic Disorders

    Brown Adipose Tissue – Novel Therapeutic to Treat Obesity and Related Metabolic Disorders BAT is a specialized adipose tissue • High metabolic activity • Able to dissipate energy, fatty acids, glucose to produce heat • Present in adult humans in small quantities BAT WAT 4

  5. Slide 5: Pre-clinical studies demonstrate that BAT transplants have therapeutic benefits

    Pre-clinical studies demonstrate that BAT transplants have therapeutic benefits 5

  6. Slide 6: ThermoStem® - development of a bioengineered human BAT construct

    ThermoStem® - development of a bioengineered human BAT construct • BRT has procured a large collection of human brown and white Generation 1 adipose tissues and cellular library BADSC/Scaffold • Isolated and characterized a novel allogeneic brown adipose stem cell population • Generation 1: BADSC/Sc

  7. Slide 7: Generation 1 - Tissue procurement/cell isolation

    Generation 1-Tissue procurement/cell isolation A B D F C E Fig. 1.(A) Patient demographics. Abbreviations: HDL, high-density lipoprotein; HbA1c. Glycosylated hemoglobin; BMI, body mass index; TG, triacylglycerol. Data are represented as means ± s.d. (B) Biopsy of human mediastinal adipose depot from

  8. Slide 8: Generation 1 - Cell characterization

    Generation 1-Cell characterization A B C F D G E H Tubulin 1 2 ~53 kDa UCP1 1 2 ~33 kDa Fig. 2. (A) Gene expression profile comparing undifferentiated brown adipose derived stem cells to undifferentiated white adipose derived stem cells derived from subcutaneous adipose tissue. Genes in red are asso

  9. Slide 9: Generation 1 - Scaffold delivery

    Generation 1-Scaffold delivery A B C 100 μm 100 μm 100 μm D E F G 500 μm 500 μm 500 μm 500 μm H I J K L * 200 μm 200 μm 200 um 50 μm Fig.4. In vitro culture of BADSCs. Representative bright field images of differentiated cells (A) prior to passaging and post-passaging and centrifugation (B) adherent

  10. Slide 10: Generation 1 - Metabolic function

    Generation 1-Metabolic function A B Fig. 3. (A) Functional mitochondrial respiration assay of brown adipose derived stem cells differentiated into brown adipocytes at 7, 14 and 21 days post differentiation. (B) Fatty acid uptake of brown fat differentiated brown adipose derived stem cells at 7, 14 a

  11. Slide 11: Generation 2 - UCP-1 Expression

    Normalized Expression H 0 1 2 0.5 1.5 2.5 um an B B A Gene/TBP Expression Pr AT relative to StemPro e- Di ff. G 0 1000 2000 3000 4000 5000 Po en St 1 ND em st Pr -D o i ff .G en 1 Ge Pr n1 e- Di ff. UCP1 Ge G n2 Po en UCP1 st 2 ND -D i ff 0 1 2 3 4 .G St en em Pr 2 o Su bQ Ge W n1 A T ND Vi FABP4 Ge

  12. Slide 12: Generation 2 - Delivery Device Loading/Human BAT Construct

    Generation 2-Delivery Device Loading/Human BAT Construct HE BF DAPI/Perilipin/UCP1 A GM DIFF-1 DIFF-2 D0 D1 D2 D5 D26 BAGs Device Adipocyte differentiation induction - RNA isolation Formation Loading - Histology / Immunostaining B D E DAPI Perilipin UCP1 FABP4 ADIPSIN PPARg CEBPa LEPTIN 2000 50 16 1

  13. Slide 13: Next Steps

    Next Steps • Small animal model using generation 2 device. • Explore other delivery systems • Study secretome of BADSC • Explore use for other indications 13

  14. Slide 14: Thank You

    biorestorat\|ve therapies THANK YOU

BioRestorative Therapies — ASGCT 2019 on 6ix